Get started
Author

Bang.an Peng

Observed name: B. Peng
ORCID: 0009-0006-9065-4914
Observed ORCID: 0009-0006-9065-4914
OpenAlex ID: A5001748686
Regulatory aspects of clonally expanded B-1 (CD5+B) cells
1992 · E. S. Raveché, J. Phillips, et al. · International Journal of Clinical & Laboratory Research · 11
Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025 · Ying Cheng, Jie Wang, et al. · Clinical Cancer Research · 9
Data from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025 · Ying Cheng, Jie Wang, et al.
Supplementary Figure S5 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025 · Ying Cheng, Jie Wang, et al.
PDF
Supplementary Table S1 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025 · Ying Cheng, Jie Wang, et al.
PDF
Supplementary Figure S3 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025 · Ying Cheng, Jie Wang, et al.
PDF
Supplementary Figure S1 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025 · Ying Cheng, Jie Wang, et al.
Supplementary Table S2 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025 · Ying Cheng, Jie Wang, et al.
PDF
Supplementary Figure S2 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025 · Ying Cheng, Jie Wang, et al.
PDF
Supplementary Table S3 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025 · Ying Cheng, Jie Wang, et al.
PDF
Supplementary Table S4 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025 · Ying Cheng, Jie Wang, et al.
PDF
Supplementary Figure S4 from Phase I/II Study of Tifcemalimab, an Anti–B- and T-lymphocyte Attenuator Antibody, in Combination with Toripalimab in Previously Treated Advanced Lung Cancer
2025 · Ying Cheng, Jie Wang, et al.
PDF
Works count: 12
Citation count: 19
H-index: 2
I10-index: 1
Year
Topic
Type